---
title: Mezigdomide is effective alone and in combination with Menin inhibition in
  pre-clinical models of KMT2A-r and NPM1c AML
date: '2023-12-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38096371/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231215170556&v=2.18.0
source: Blood
description: Small molecules that target the MENIN-KMT2A protein-protein interaction
  (Menin inhibitors) have recently entered clinical trials in lysine methyltransferase
  2A (KMT2A, MLL1) rearranged (KMT2A-r) and nucleophosmin mutant (NPM1c) acute myeloid
  leukemia (AML) and are demonstrating encouraging results. However, rationally chosen
  combination therapy is needed to improve responses and prevent resistance. We have
  previously identified IKZF1/IKAROS as a target in KMT2A-r AML and shown in ...
disable_comments: true
---
Small molecules that target the MENIN-KMT2A protein-protein interaction (Menin inhibitors) have recently entered clinical trials in lysine methyltransferase 2A (KMT2A, MLL1) rearranged (KMT2A-r) and nucleophosmin mutant (NPM1c) acute myeloid leukemia (AML) and are demonstrating encouraging results. However, rationally chosen combination therapy is needed to improve responses and prevent resistance. We have previously identified IKZF1/IKAROS as a target in KMT2A-r AML and shown in ...